AD diagnostic testing is a hot topic especially in light of recent Kinsula approval. Besides the new paper below, PT217 is also listed in the revised criteria for diagnosis and staging of Alzheimer's disease by Alzheimer's Association Workgroup. https://lnkd.in/gqEJxDiK “Early-changing Core 1 biomarkers (amyloid positron emission tomography [PET], approved cerebrospinal fluid biomarkers, and accurate plasma biomarkers [especially phosphorylated tau 217]) map onto either the amyloid beta or AD tauopathy pathway.” “Thus, our definition of Core 1 plasma tests that suffice as standalone diagnostic tests for AD is those with a minimum accuracy of 90% to detect abnormal amyloid PET in the intended-use population, or, more simply, plasma tests whose diagnostic performance is equivalent to that of approved CSF assays (Box 2). Our position is that BBM that achieve this diagnostic performance benchmark should be considered on equal footing with established PET and CSF biomarkers for diagnosis of AD.” Find out more about plasma PT217 from Mayo Clinic Labs that has an overall accuracy of 93% here: https://lnkd.in/gaAqkiBb #Alzheimer #Diagnostic #PlasmaBiomarkers #PhosphoTau217 #MildCognitiveImpairement #AmyloidPathology #Guidelines #MayoClinicLabs
My colleagues and I have published an article in Alzheimer’s & Dementia where we demonstrate that a blood-based biomarker, pTau217, can predict brain amyloid levels across a broad spectrum of individuals—from those with no cognitive impairment to those with mild cognitive impairment or dementia. Notably, it can predict a wider range of brain amyloid levels compared to the commonly used cerebrospinal fluid (CSF) biomarker, Ab42/Ab40. The ability to directly predict brain amyloid levels across a wide range makes this blood-based biomarker an invaluable tool for patient screening and monitoring, both in clinical trials and everyday clinical practice. Read the article here: https://lnkd.in/eREvWwme #BBM #PET #diagnosis #monitoring #machinelearning #aiml #alzheimer #biomarker #precisonmedicine #alzheimersdisease #neurology #screening #earlydetection #clinicalpractice #dementia #cognitivedecline #neuroscience
